Efficacy of treating allergic dermatoses with the original drug of topical mometasone furoate in standard clinical practice

K.M. Khobzei, O.B. Tymkiv
{"title":"Efficacy of treating allergic dermatoses with the original drug of topical mometasone furoate in standard clinical practice","authors":"K.M. Khobzei, O.B. Tymkiv","doi":"10.30978/ujdvk2023-4-51","DOIUrl":null,"url":null,"abstract":"Skin allergic dermatoses represent a significant issue and account for one of the commonest causes for patients seeking consultations with dermatologists. The prevalence of atopic dermatitis (AD) in the general population reaches 10 % among adults and 20 % among children. Despite the significant deepening of our understanding of the complex pathogenesis of allergic dermatoses and the establi­shing role of many genetic and epigenetic factors in provoking exacerbations of AD or predisposition to the development of allergic contact dermatitis (ACD), topical corticosteroids remain the cornerstone treatment for flare­ups of these disorders.We investigated the effectiveness of the mometasone furoate 0.1 % topical cream (Elocom®) for the treatment of patients with allergic dermatoses. The study included 20 patients whose participation was determined based on clinical anamnesis and examination, diagnosed with AD (n = 13) and ACD (n = 7). The duration of treatment was from 7 to 30 days. During the study, all the 20 patients (100 %) noted a significant improvement in the skin condition, 18 (90 %) — improvement during the first days of treatment. Throughout the study, none of the patients experienced side effects linked to the use of the medication. The average value of the Dermatology Life Quality Index among patients before the start of treatment was (13.0 ± 6.83) points, after treatment — (4.8 ± 3.56) points. A decrease in the Index by an average of 8.2 points indicates a significant improvement in the patients’ quality of life. The obtained results demonstrate the high effectiveness of topical mometasone furoate in the treatment of patients with allergic dermatoses. Since these results were obtained in the process of observational research, they have significant practical value.Thus Elokom®, a topical mometasone furoate preparation, is advisable for the treatment of allergic dermatoses in routine clinical practice.","PeriodicalId":23420,"journal":{"name":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30978/ujdvk2023-4-51","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Skin allergic dermatoses represent a significant issue and account for one of the commonest causes for patients seeking consultations with dermatologists. The prevalence of atopic dermatitis (AD) in the general population reaches 10 % among adults and 20 % among children. Despite the significant deepening of our understanding of the complex pathogenesis of allergic dermatoses and the establi­shing role of many genetic and epigenetic factors in provoking exacerbations of AD or predisposition to the development of allergic contact dermatitis (ACD), topical corticosteroids remain the cornerstone treatment for flare­ups of these disorders.We investigated the effectiveness of the mometasone furoate 0.1 % topical cream (Elocom®) for the treatment of patients with allergic dermatoses. The study included 20 patients whose participation was determined based on clinical anamnesis and examination, diagnosed with AD (n = 13) and ACD (n = 7). The duration of treatment was from 7 to 30 days. During the study, all the 20 patients (100 %) noted a significant improvement in the skin condition, 18 (90 %) — improvement during the first days of treatment. Throughout the study, none of the patients experienced side effects linked to the use of the medication. The average value of the Dermatology Life Quality Index among patients before the start of treatment was (13.0 ± 6.83) points, after treatment — (4.8 ± 3.56) points. A decrease in the Index by an average of 8.2 points indicates a significant improvement in the patients’ quality of life. The obtained results demonstrate the high effectiveness of topical mometasone furoate in the treatment of patients with allergic dermatoses. Since these results were obtained in the process of observational research, they have significant practical value.Thus Elokom®, a topical mometasone furoate preparation, is advisable for the treatment of allergic dermatoses in routine clinical practice.
在标准临床实践中使用糠酸莫米松外用原药治疗过敏性皮肤病的疗效
皮肤过敏性皮肤病是一个重要问题,也是患者向皮肤科医生求诊的最常见原因之一。特应性皮炎(AD)在成年人和儿童中的发病率分别达到 10%和 20%。尽管我们对过敏性皮肤病复杂的发病机制有了更深入的了解,并确定了许多遗传和表观遗传因素在引起过敏性接触性皮炎(ACD)恶化或易患过敏性接触性皮炎中的作用,但外用皮质类固醇仍是治疗这些疾病复发的基石。这项研究包括 20 名患者,根据临床病史和检查结果决定是否参加,他们被诊断为 AD(13 人)和 ACD(7 人)。治疗时间为 7 至 30 天。在研究过程中,所有 20 名患者(100%)的皮肤状况都得到了明显改善,其中 18 名患者(90%)在治疗的最初几天皮肤状况就得到了改善。在整个研究过程中,没有一名患者出现与用药有关的副作用。治疗开始前,患者的皮肤科生活质量指数平均值为(13.0 ± 6.83)分,治疗后为 (4.8 ± 3.56) 分。该指数平均下降了 8.2 点,表明患者的生活质量有了显著改善。这些结果表明,糠酸莫米松外用药对过敏性皮肤病患者的治疗非常有效。因此,在常规临床实践中,建议将糠酸莫米松外用制剂 Elokom® 用于过敏性皮肤病的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信